Latest Celosia Therapeutics News & Updates

See the latest news and media coverage for Celosia Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Celosia Therapeutics

Gene therapy developer for neurodegenerative diseases

celosiatx.com

Headquarters: Sydney, Australia
Founded year: 2022
Company type: Private company
Number of employees: 1–5

Last updated Today

Latest news about Celosia Therapeutics

In short: Celosia Therapeutics dosed the first patient in its Phase 1b clinical trial of the gene therapy CTx1000 for Amyotrophic Lateral Sclerosis (ALS).

Company announcements

May 4 Celosia Therapeutics

Celosia Therapeutics doses first patient in Phase 1 study

The study tests CTX 1000's safety and efficacy for ALS patients at Macquarie University Hospital. Professor Lars Ittner highlights this milestone after 17 years of development.

March 24 Celosia Therapeutics

Celosia Therapeutics doses first patient in Phase 1b KOANEWA trial

The trial evaluates CTx1000 gene therapy targeting TDP-43 in ALS patients at Macquarie University Hospital. CEO highlights milestone for ALS community.

February 16 Celosia Therapeutics

Celosia secures second U.S. patent for CTx1000 therapy

This strengthens IP foundation amid clinical preparation for first-in-human dosing. The team advances toward patient impact.

2 December 2025 Celosia Therapeutics

Celosia Therapeutics mourns Iomar Barrett's passing

Iomar Barrett was a courageous ALS patient, visionary Series A investor, and steadfast supporter who shaped the company's foundation and mission for ALS therapies.

Media coverage

March 23 Morningstar

Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 23, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing...

17 February 2025 The Australian

Macquarie University spin-out Celosia Therapeutics nabs $16.8m to take ALS treatment to trial

Celosia Therapeutics, a Macquarie University spin-out, has picked up the funds by way of Uniseed for its lead treatment - called CTX-1000 - which is...

Never miss news about Celosia Therapeutics

Track Celosia Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Celosia Therapeutics competitors & trending companies

Browse news for competitors to Celosia Therapeutics and other trending companies.